Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sanofi winthrop industrie - liksisenatide - cukrinis diabetas, 2 tipas - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutidas - cukrinis diabetas, 2 tipas - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. už studijų rezultatus, atsižvelgiant į derinius, poveikis glycaemic kontroliuoti širdies ir kraujagyslių įvykių, gyventojų, studijavo, žr. skirsnius 4. 4, 4. 5 ir 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - eksenatidas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - bydureon yra nurodyta suaugusiųjų 18 metų ir vyresni, su 2 tipo cukriniu diabetu, siekiant pagerinti glycaemic kontrolės kartu su kitais gliukozės mažinančius vaistus, kai terapijos naudojimo, kartu su dieta ir mankšta, neužtikrina adekvačios glycaemic kontrolės (žr. skyrių 4. 4, 4. 5 ir 5. 1, jei yra duomenų apie skirtingus derinius). bydureon fluorouracilu gydyti 2 tipo cukrinis diabetas kartu su:metforminsulphonylureathiazolidinedionemetformin ir sulphonylureametformin ir thiazolidinedionein suaugusiųjų, kurie yra ne pasiekti tinkamą glycaemic kontrolės maksimaliai toleruojama dozes šių žodžiu terapija.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novo nordisk a/s - žmogaus insulinas - cukrinis diabetas - narkotikai, vartojami diabetu - cukrinio diabeto gydymas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novo nordisk a/s - žmogaus insulinas - cukrinis diabetas - narkotikai, vartojami diabetu - cukrinio diabeto gydymas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

marvel lifesciences ltd - žmogaus insulinas - cukrinis diabetas - diabetinių.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novo nordisk a/s - repaglinidas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - repaglinidas yra skiriamas pacientams, sergantiems 2 tipo cukriniu diabetu (ne-nuo insulino nepriklausomu cukriniu diabetu (niddm)), kurių hiperglikemija gali nebe būti gerai kontroliuojama dietinėmis dieta, svorio sumažinimo ir fizinio. repaglinidas taip pat vartojamas kartu su metforminu 2 tipo cukriniu diabetu sergantiems pacientams, kurių vien tik metforminas kontroliuojamas nepakankamai. gydymas turi būti pradėtas kaip papildoma priemonė kartu su dieta ir fiziniais pratimais sumažinti kraujo gliukozės dėl valgiai.